SCHEMBL5859382

SCHEMBL5859382

COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)C(C)(C)N)cc1)c1ccc2c(c1)OOCC2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.36
NPC1 O15118 1/20 0.31
CASP3 P42574 1/20 0.31
RAB9A P51151 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
SENP7 Q9BQF6 1/20 0.31
KMT2A Q03164 1/20 0.31
CTDSP1 Q9GZU7 1/20 0.31
AAK1 Q2M2I8 1/20 0.31
MAPK14 Q16539 4/20 0.30
ALOX5 P09917 1/20 0.30
CRBN Q96SW2 1/20 0.30
ALDH1A1 P00352 1/20 0.30
LMNA P02545 1/20 0.30
TP53 P04637 1/20 0.30
POLB P06746 1/20 0.30
THRB P10828 1/20 0.30
BLM P54132 1/20 0.30
TDP1 Q9NUW8 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5857064 0.94 RXFP1 (0.36) NPC1RAB9ASMN1; SMN2KMT2AMAPK14
SCHEMBL5856878 0.89 NAMPT (0.31)
SCHEMBL5857845 0.89 CA12 (0.32) CASP3KMT2AALDH1A1POLBBLM
SCHEMBL5858270 0.86 RXFP1 (0.37) NOTUMNPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL3943961 0.85 NOTUM (0.39) NOTUMNPC1CASP3RAB9ASMN1; SMN2
SCHEMBL5858412 0.84 MITF (0.31)
SCHEMBL5857588 0.84 AAK1 (0.48) AAK1ALDH1A1LMNA
SCHEMBL5858056 0.84 BACE1 (0.34) NOTUMSMN1; SMN2TP53
SCHEMBL5858470 0.82 NOTUM (0.41) NOTUMSMN1; SMN2KMT2ACTDSP1ALDH1A1
SCHEMBL5856812 0.82 RXFP1 (0.35) NPC1RAB9ASMN1; SMN2KMT2AAAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7148249-B2 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-12-12 US claimed
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-03-10 US claimed
US-7148249-B2 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-12-12 US disclosed
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments CDK1, CDK2, CDK3 NOTUM 3379/4885NPC1 4723/4885CASP3 848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.